BD introduces Surgiphor surgical wound irrigation system in Europe to improve surgical care

UK—Becton, Dickinson and Company (BD), a leading global medical technology firm, has introduced its Surgiphor surgical wound irrigation system to the European market.

The system has received CE approval and is now available in selected countries across the region.

Surgiphor is formulated as a pre-mixed, sterile irrigation solution designed to help clear surgical wounds of debris and foreign materials during procedures, eliminating the need for hospital staff to prepare the solution on-site.

This irrigation solution includes a trusted antiseptic preservative that reduces bacterial contamination, helping lower the risk of surgical site infections.

Surgiphor also offers an ergonomic design that allows surgical teams to apply the solution quickly and easily.

Rian Seger, BD’s worldwide president of surgery, highlighted the importance of this launch, stating it represents a major step forward in improving surgical care across Europe.

Seger noted that because surgical site infections result from multiple factors, they remain a significant challenge affecting patient recovery and healthcare systems.

Surgiphor supports healthcare professionals by enabling evidence-based practices, such as surgical wound irrigation, to help minimize infection risk, accelerate healing, and enhance overall surgical safety.

This introduction reflects BD’s ongoing commitment to advancing surgical tools and solutions that prioritize patient safety and practical usability.

In addition to this European launch, BD recently announced a USD35 million investment to enhance manufacturing capabilities for its PosiFlush prefilled flush syringes at its plant in Columbus, Nebraska, USA.

The expansion is projected to create 50 new jobs and support rising demand from hospitals and health systems across the United States.

Furthermore, BD has secured 510(k) clearance from the US Food and Drug Administration and achieved CE marking under the European Union’s In Vitro Diagnostic Regulation for its bacterial panels designed for use with the BD COR System.

These developments emphasize BD’s strategic focus on delivering innovative, regulatory-approved healthcare products that meet the evolving needs of global medical communities.